Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Boughey Discusses the Z11 Trial in Breast Cancer

April 8th 2014

Judy C. Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses implications for axillary radiation following review of the ACOSOG Z11 trial.

I-SPY 2 Trial Graduates Neratinib for HER2-Positive Breast Cancer

April 7th 2014

The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer

Palbociclib Dramatically Improves PFS in Updated Phase II Findings

April 7th 2014

The combination of palbociclib and letrozole more than doubled PFS and showed a nonâ€“statistically significant 4.2-month improvement in OS for patients with ER-positive, HER2-negative metastatic breast cancer.

CDK4/6 Inhibitor LY2835219 Shows Promise in Early Study

April 7th 2014

The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with HR-positive metastatic breast cancer.

Breast Cancer Patients Fare Worse When Adjuvant Chemotherapy Is Delayed

April 4th 2014

Breast cancer patients whose chemotherapy is initiated >60 days following surgery experience worse survival outcomes

Dr. Muss on Cardiac Function in Breast Cancer Patients

April 3rd 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses maximizing cardiac function in patients with breast cancer.

A Look at I-SPY 2: Novel Trial Design May Expand the Scope of Oncology Drug Development

April 2nd 2014

Amid a growing recognition of the need to improve the process of developing oncology drugs, the novel I-SPY 2 clinical trial in breast cancer has demonstrated the potential to deliver new, effective treatment options more rapidly to patients who would most benefit while dramatically reducing the time and costs currently required to evaluate experimental therapies.

Dr. Silverstein Gives an Overview of the VNPI

April 1st 2014

Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, gives an overview of the Van Nuys Prognostic Index for DCIS.

Breast Cancer Expert Offers Views on Promising Strategies

April 1st 2014

Now that targeted therapies are available for the treatment of various subtypes of breast cancer, and many novel agents are under investigation, it is important for the oncology community to follow the latest advancements to give patients the best available options.

Dr. Kuerer Discusses Sentinel Node Clipping

March 28th 2014

Henry M. Kuerer, MD, PhD, FACS, professor of surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, discusses sentinel node clipping for post-chemotherapy identification.

Yoga Lessens Fatigue and Inflammation in Breast Cancer Survivors

March 27th 2014

Breast cancer survivors who took two yoga classes a week for 3 months after treatment were less fatigued and demonstrated less systemic inflammation than their counterparts who did not take the classes

Dr. Carlson on Contralateral Prophylactic Mastectomies

March 21st 2014

Grant W. Carlson, MD, professor of surgery, Emory University School of Medicine, chief, Division of Plastic Surgery, Emory University Hospital, explains why more women with breast cancer are electing to get contralateral prophylactic mastectomies (CPMs)

Antibody-Drug Conjugates and T-DM1

March 21st 2014

Human epidermal growth factor receptor 2 (HER2)-positive disease accounts for 20% to 25% of breast cancers, as represented by amplification of the HER2 gene and/or HER2 protein overexpression

Dr. Tripathy on Personalized Therapies in Advanced BC

March 20th 2014

Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses new personalized therapies on the horizon for advanced breast cancer.

Dr. Schneiderman on Cancer Drugs and Futility Policies

March 18th 2014

Lawrence J. Schneiderman, MD, professor emeritus, Medicine/Family & Preventive Medicine, University of California, San Diego (UCSD), discusses futility policies in relation to cancer drugs.

Novel Clinical Trial "Graduates" Two Promising Agents

March 18th 2014

The first results from the I-SPY 2 trial, which is evaluating novel agents in the neoadjuvant treatment of breast cancer, show encouraging possibilities for veliparib (ABT-888) and neratinib (PB272).

Dr. White on Ablative Radiotherapy for MBC

March 14th 2014

Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, discusses the use of ablative radiotherapy in patients with metastatic breast cancer.

Dr. Salerno on the Importance of Clinical Researchers

March 12th 2014

Judith A. Salerno, MD, MS, president, CEO, Susan G. Komen, discusses federal funding for research and the importance of gaining funds though private philanthropy to support clinical researchers.

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

March 12th 2014

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

New Trial Models Aim to Accelerate Pace of Neoadjuvant Approvals

March 10th 2014

New models have emerged for examining novel breast cancer treatments in the neoadjuvant setting that avoid the lengthy process of standard, large adjuvant trials.